Currently, there are 61.97M common shares owned by the public and among those 50.25M shares have been available to trade.
The company’s stock has a 5-day price change of 6.77% and -26.35% over the past three months. CGTX shares are trading -54.80% year to date (YTD), with the 12-month market performance down to -84.54% lower. It has a 12-month low price of $0.22 and touched a high of $2.54 over the same period. CGTX has an average intraday trading volume of 761.14K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.39%, -13.81%, and -38.18% respectively.
Institutional ownership of Cognition Therapeutics Inc (NASDAQ: CGTX) shares accounts for 9.13% of the company’s 61.97M shares outstanding.
It has a market capitalization of $19.66M and a beta (3y monthly) value of 0.74. The earnings-per-share (ttm) stands at -$0.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.80% over the week and 9.23% over the month.
Earnings per share for the fiscal year are expected to increase by 52.62%, and 31.29% over the next financial year. EPS should grow at an annualized rate of 32.88% over the next five years, compared to -16.44% over the past 5-year period.
Looking at the support for the CGTX, a number of firms have released research notes about the stock. B. Riley Securities stated their Buy rating for the stock in a research note on December 19, 2024, with the firm’s price target at $1-$1.50. Oppenheimer was of a view on November 03, 2021 that the stock is Outperform, while B. Riley Securities gave the stock Buy rating on November 03, 2021, issuing a price target of $27.
